Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 26 2019 - 7:00AM
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutic compounds to treat disease through the inhibition of
the complement system, today announced that the company will
participate in the following upcoming investor conferences in
December:
- Evercore ISI 2019 Healthcare Conference on Tuesday,
December 3, 2019 at 2:20 p.m. ET in Boston,
MA
- Piper Jaffray 2019 Healthcare Conference on Thursday,
December 5, 2019 at 12:30 p.m. ET in New York,
NY
Cedric Francois, CEO and co-founder of Apellis, will participate
in a fireside chat at the Evercore ISI 2019 Healthcare Conference
and at the Piper Jaffray 2019 Healthcare Conference.
The events will be available via live webcast from the “Events
and Presentations” page of the “Investors and Media” section of the
company’s website
at http://investors.apellis.com/events-and-presentations.
Replays of the webcasts will be available for 90 days following the
events.
About Apellis Apellis Pharmaceuticals,
Inc. is a clinical-stage biopharmaceutical company focused on
the development of novel therapeutic compounds for the treatment of
a broad range of life-threatening or debilitating autoimmune
diseases based upon complement immunotherapy through the inhibition
of the complement system at the level of C3. Apellis is the first
company to advance chronic therapy with a C3 inhibitor into
clinical trials. For additional information about Apellis and
APL-2, please visit http://www.apellis.com.
Investor Contact:Sam Martin / Maghan
MeyersArgot Partnerssam@argotpartners.com /
maghan@argotpartners.com212.600.1902
Media Contact:Tracy
Vineis tracy.vineis@apellis.com617.420.4839
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2023 to Apr 2024